IMAC Holdings, Inc. has launched Ignite Proteomics LLC, a new subsidiary focused on enhancing cancer treatment personalization through protein-level analysis. This initiative aims to improve the ...

When Matthew Padula was diagnosed with a rare bladder cancer in 2020, he knew there was a challenging road ahead of him. As a researcher at the University of Technology Sydney, his first instinct was ...

At this year's American Association for Cancer Research annual meeting, the conversation around cancer research felt noticeably different compared to the last time I attended. Genes and mutations were ...

Innovative deep proteomic profiling reveals promising results from a blood-based test for early breast cancer, showcasing high sensitivity and specificity, explains Justin Drake, PhD. Current standard ...

For the past 20 years, many of the dramatic improvements in cancer outcomes can be attributed to personalized cancer treatments based upon DNA mutations in a tumor. Targeted therapies — often one pill ...

When a cell divides, a small section of the telomere of each chromosome is worn away. While most cells use the enzyme telomerase to mitigate this loss, about 10–15% of cancers use a different ...

SAMBAI, a team funded through the Cancer Grand Challenges initiative, reported that Akoya Biosciences’ PhenoCycler ®-Fusion system will be the foundational spatial proteomics technology used to ...

n this study, 773 untreated breast cancer patients from all over China were collected and followed up for at least 5 years. We obtained clinical data from 773 cases, RNA sequencing data from 752 cases ...

Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative healthcare solutions, proudly announces the launch of an ...